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Summary
Objective: Glucosamine sulfate (GS) is a commonly used drug for the treatment of osteoarthritis. The mechanism of the action of this drug
does, however, remain to be elucidated. In human osteoarthritic chondrocytes (HOC) stimulated with a proinflammatory cytokine, we studied
whether GS could modify the NFκB activity and the expression of COX-2, a NFκB-dependent gene.
Methods: Using HOC in culture stimulated with interleukin-1 β (IL-1β), the effects of GS on NFκB activation, nuclear translocation of
NFκB/Rel family members, COX-1 and COX-2 expressions and syntheses and prostaglandin E2 (PGE2) concentration were studied.
Results: GS significantly inhibited NFκB activity in a dose-dependent manner, as well as the nuclear translocation of p50 and p65 proteins.
Furthermore, GS-preincubated IL-1β-stimulated HOC showed an increase in IκBα in the cell cytoplasm in comparison with HOC incubated
with IL-1β alone. GS also inhibited the gene expression and the protein synthesis of COX-2 induced by IL-1β, while no effect on COX-1
synthesis was seen. GS also inhibited the release of PGE2 to conditioned media of HOC stimulated with IL-1β.
Conclusions: GS inhibits the synthesis of proinflammatory mediators in HOC stimulated with IL-1β through a NFκB-dependent mechanism.
Our study further supports the role of GS as a symptom- and structure-modifying drug in the treatment of OA.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All rights reserved.
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Introduction
Osteoarthritis (OA) is the most common joint disorder with
an immense socio-economic impact. OA is characterized
by quantitative and qualitative changes in the architecture
and composition of all the joint structures1,2. An altered
imbalance between the biosynthesis and the degradation
of matrix components leads to a progressive destruction of
the tissue3.
The localized nature and lack of signs of general inflam-
mation distinguish OA from systemic inflammatory dis-
eases, such as rheumatoid arthritis, although local
inflammatory activity is a well-recognized component of
OA. In the past years, some investigators have pointed out
the key role of inflammation in OA4–6. Recent studies have
shown a superinduction of proinflammatory genes and their
corresponding gene products in OA articular cartilage
(reviewed in Amin et al.)7. In fact, interleukin-1 β (IL-1β), a
well-recognized proinflammatory cytokine, is locally in-
creased during the osteoarthritic process. IL-1β induces a
large cascade of events that leads to cartilage damage,
such as the synthesis of metalloproteases and extracellular
matrix proteins that are absent in normal cartilage, the
release of other inflammatory mediators, the inhibition of
chondrocyte proliferation and induction of cell death8,9.
Nuclear factor kappa B (NFκB) is an ubiquitous protein
that specifically binds to DNA consensus sequences, acti-
vating its transcription. NFκB exists in the cytoplasm in an
inactive form. When an extracellular stimulus induces the
phosphorylation of an inhibitory subunit (a member of IκB
family) and its subsequent degradation, the active complex
becomes capable of migrating to nucleus, where it recog-
nizes the consensus sequences in DNA. NFκB-binding
sites are present in the promoter regions of many genes
involved in the pathophysiology of joint inflammation and
tissue destruction10,11.
Some symptomatic slow-acting drugs, such as glucos-
amine sulfate (GS), have proved effective in relieving the
symptoms of OA12–14. Although GS has been proposed as
a scavenger of free oxygen radicals, the mechanism of
action of this drug remains to be elucidated15. Recent
reports suggest that the effects of glucosamine compounds
could be due to the control of inflammatory genes expres-
sion, but the conclusions seem to be contradictory16,17.
The aim of the present work was to investigate if GS is
able to modify the NFκB activation induced by proinflam-
matory cytokines, such as IL-1β in osteoarthritic chondro-
cytes. We also looked for subunits participating in NFκB
complexes along with the specific activity of GS upon these
components. In addition, we studied the effect of GS on the
expression and synthesis of a NFκB-dependent gene, such
as COX-2. We also assessed whether GS could modify the
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release of prostaglandin E2 (PGE2) to the conditioned
media of HOC stimulated by IL-1β.
Methods
CELL CULTURE
Human osteoarthritic cartilage was obtained after routine
total knee replacements from informed donors. Articular
cartilages from the femoral condyles and the tibial plateaus
were aseptically dissected. Chondrocytes were obtained
after sequential digestion with pronase (Roche, 10 g/l) for
30 min and collagenase type IV (Sigma, 1 g/l) for 6 h, both
in 0.9% NaCl. Chondrocytes were grown to confluence in
DMEM (BioWhittaker) supplemented with 10% fetal calf
serum (BioWhittaker), 60 U/ml penicillin, 60 µg/ml strepto-
mycin and 2 mmol/l glutamine (BioWhittaker) at 37°C in the
presence of 5% CO2. Experiments were performed with
first or second passage cells. In each experiment, cells
were made quiescent for 48 h in DMEM medium without
serum and stimulated at different times with IL-1β (Immuno-
genex). Where indicated, cells were preincubated
with equimolar concentrations of GS (crystalline form,
Rottapharm), N-acetylglucosamine (N-AcG, Sigma) or
galactosamine hydrochloride (Gal, Sigma) for 30 min, and
these compounds were maintained during the whole period
of incubation.
PREPARATION OF NUCLEAR AND CYTOSOLIC EXTRACTS
Nuclear and cytosolic extracts were obtained as previ-
ously described18. After the incubation period, chondro-
cytes were trypsinized and resuspended in buffer A
(10 mmol/l HEPES, pH 7.8, 15 mmol/l KCl, 2 mmol/l MgCl2,
0.1 mmol/l ethylenediaminetetraacetic acid (EDTA),
1 mmol/l dithiothreitol (DTT), and mmol/l phenylmethylsul-
fonyl fluoride (PMSF)) and were homogenized. Nuclei and
cytosolic fractions were separated by centrifugation at
1000×g for 10 min. The cytosolic fractions (supernatants)
were stored at 80°C until IκBα analysis. The nuclei (pellets)
were washed twice in buffer A and resuspended in the
same buffer, with a final concentration of 0.39 mol/l KCl.
Nuclei were extracted for 1 h at 4°C and centrifuged at
100 000×g for 30 min. Supernatants were dialyzed in buffer
C (50 mmol/l HEPES, pH 7.8, 50 mmol/l KCl, 10% glycerol,
1 mmol/l PMSF, 0.1 mmol/l EDTA, and 1 mmol/l DTT) and
were then cleared by centrifugation and stored at 80°C.
The protein concentration was determined by the bicin-
choninic acid (BCA) method.
ELECTROPHORETIC MOBILITY SHIFT ASSAY
Transcription factor activity was determined as previ-
ously described18. Briefly, NFκB or AP-1 consensus
oligonucleotides (5′-AGTTGAGGGGACTTTCCCAGGC-3′)
and (5′-CGCTTGATGAGTCAGCCGGAA-3′), respectively,
were [32P] end-labeled with -[32P]ATP and T4 polynucleo-
tide kinase (Promega). Nuclear extracts (5 µg) were equili-
brated for 10 min in a binding buffer (4 glycerol, 1 mmol/l
MgCl2, 0.5 mmol/l EDTA, 0.5 mmol/l DTT, 50 mmol/l NaCl,
10 mmol/l Tris–HCl, pH 7.5 and 50 g/ml of poly(dI-dC);
Pharmacia LKB), and then the labeled probe (0.35 pmol)
was added and incubated for 20 min at room temperature.
To establish the specificity of the reaction, negative controls
without cell extracts and competition assays with a 100-fold
excess of unlabeled oligonucleotide were performed. In
competition assays, the corresponding unlabeled probe
was added to the reaction mixture 10 min prior to the
addition of the labeled probe. Hela cell nuclear extract was
used as a positive control of the technique (data not
shown). For supershift assays, 1 µg of antibodies was
added and incubated with nuclear extracts for 1 h, prior to
the addition of labeled probe. The specificity of these
antibodies was tested by Western blots (data not shown).
The reaction was stopped by adding gel-loading buffer
(250 mmol/l Tris–HCl, 0.2% bromophenol blue, 0.2% xy-
lene cyanol, and 40% glycerol) and run on a nondenaturing
4% acrylamide gel in Tris–Borate. The gel was dried and
exposed to X-ray film.
IMMUNOFLUORESCENCE STAINING
Chondrocytes were grown in eight-well Titer-Tek slides
(Costar). To study NFκB proteins, quiescent cells were
incubated with 10 U/ml IL-1β with or without GS for 60 min.
After incubation, cells were washed, fixed in methanol/
acetone (50:50 v/v) for 1 h at −20°C and were then treated
with 0.1% Triton X-100 for 1 min on ice to permeabilize
nuclear membranes. Cells were incubated with 6% normal
goat serum and 4% bovine serum albumin (BSA) in phos-
phate buffered saline (PBS) (9.1 mmol/l dibasic sodium
phosphate, 1.7 mmol/l monobasic sodium phosphate,
150 mmol/l NaCl, pH 7.4) for 1 h at 37°C. Rabbit polyclonal
antibodies against p50 and p65 subunits (10 µg/ml) (Santa
Cruz Biotech) were used as primary antibodies, and a
1/200 dilution of FITC-labeled goat antirabbit IgG was used
as a secondary antibody (Sigma). Controls were stained
with nonimmune serum or with the secondary antibody
alone. Preparations were mounted in a 70% glycerol
solution and examined under microscope. Images were
photographed and printed at equivalent exposures.
WESTERN-BLOT ANALYSIS
For IκBα determination, cytosolic fractions were obtained
as described in the previous discussion. For COX-1 and
COX-2 determinations, cells were homogenized with ice-
cold lysis buffer (1% Nonidet P-40 (Sigma); 0.5% SDS,
0.1 mmol/l EDTA, 1 mmol/l DTT and 1 mmol/l PMSF in
PBS). The lysates were transferred to eppendorf tubes and
centrifuged twice at 12 000×g for 10 min. Protein concen-
trations were determined by the BCA method. Similar
amounts of protein were run on SDS-polyacrylamide gel by
electrophoresis and were electrophoretically transferred to
polyvinylidene difluoride membranes (Millipore). Mem-
branes were blocked in 0.1 mmol/l Tris, pH 7.4, and
0.1 mmol/l NaCl containing 0.3% Tween-20 and 6% dry
skimmed milk for 60 min at room temperature. Then, mem-
branes were incubated overnight with anti-IκBα, anti-
COX-1 or anti-COX-2 antibodies (all from Santa Cruz
Biotech.) at 4°C. After washing, detections were made by
incubation with peroxidase-conjugated secondary anti-
bodies and developed by an enhanced chemiluminiscence
kit (ECL, Amersham). In order to ensure that equal
amounts of total proteins were charged, we also hybridized
each membrane with anti-α-tubulin (Sigma).
TOTAL RNA EXTRACTION AND ANALYSIS OF COX-2 EXPRESSION
Cells were harvested and total RNA was obtained by the
acid guanidinium–phenol–chloroform method19. Isolated
RNA was reverse transcribed and then amplified with a
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commercial kit (Access RT-PCR System®, Promega), em-
ploying specific primers of human COX-220. PCR analyses
for COX-2 and the house-keeping gene glyceraldehyde
3-phosphate dehydrogenase (GAPDH) were conducted in
the following conditions: 1 min at 94°C to denature the
double-stranded DNA, 2 min at 58°C to allow for the
annealing of the primers and 2 min at 68°C for primers
extension20. The primers employed were: (antisense)
5′-TCTTTGCCCAGCACTTCAC-3′ and (sense) 5′-
CCATTCAGGATGCTCCTGTT-3′ for COX-2 and (anti-
sense) 5′-ATACTGTTACTTATACCGATG-3′ and (sense) 5′-
AATGCATCCTGCACCACCAA-3′ for GAPDH (515 bp).
Amplifications were done for 15, 20, 25, 30 and 35 cycles in
order to establish the linearity of the reaction and to decide
the appropriate cycle number (28 for COX-2 and 20 for
GAPDH). Tubes with mixture reaction were placed on a
Thermo Cycler® (Perkin–Elmer Cetus). Then, aliquots of
each reaction were size-fractionated with 4% acrylamide–
bisacrylamide gels. The gels were dried and exposed to
X-OMAT AR films (Eastman Kodak, Rochester, NY). Auto-
radiographies were analyzed using scanning densitometry
(Molecular Dynamics). Results were expressed as arbitrary
densitometric units.
PROSTAGLANDIN E2 ASSAY
The conditioned media from HOC (cultured at
50 000 cells/well in 96 well-plates in 150 µl media) was
collected and stored at −80°C until analysis. PGE2 content
was measured by enzyme immunoassay (EIA) (Assay
Designs Inc.) according to manufacturer’s instructions.
STATISTICAL ANALYSIS
Densitometric results, expressed as arbitrary units (AU)
as n-fold over control, and PGE2 concentration (as µg/ml)
are expressed as the mean±S.E.M. Comparisons between
groups were made by Student’s t test and analysis
of variance. P values less than 0.05 were considered
significant.
Results
EFFECT OF GS, N-ACG AND GAL ON IL-1β-INDUCED NFκB
ACTIVATION
IL-1β caused a time-dependent increase in NFκB activity
in human osteoarthritic chondrocytes (HOC). The maximal
response was observed at 60 min (Fig. 1). This binding
reaction was specific since cold NFκB prevented the for-
mation of the complexes with 32P-labeled NFκB (Fig. 1,
lane C). When 60 min was established as optimal period of
incubation for NFκB binding, cells were incubated for
30 min with different doses of GS before addition of IL-1β
(10–1000 mg/l). At these doses, GS did not affect cell
viability (data not shown). As can be seen in Fig. 2,
exposure to GS did not modify NFκB binding when incu-
bated alone. However, GS-preincubated IL-1β-stimulated
HOC showed a significant inhibition of NFκB binding in a
dose-dependent manner in comparison with IL-1β-
stimulated HOC. In parallel series of experiments, we also
incubated HOC with equimolar concentrations of N-AcG or
Gal (0.02–2 mM) before IL-1β stimulation. None of these
compounds were able to significantly inhibit NFκB activa-
tion induced by IL-1β. Fig. 3 shows only the results corre-
sponding to the higher doses of the sugars, although the
effect for Gal and N-AcG was the same with minor doses
(data not shown).
In order to study whether this effect on NFκB activation
was specific for this nuclear factor, we studied whether the
increase in the nuclear translocation of AP-1, that can also
be induced by IL-1β, could be modified by GS. Equal
amounts of nuclear extracts assayed for NFκB binding
were employed to assay AP-1 binding. These studies
demonstrated that GS did not modify IL-1β-induced AP-1
binding (Fig. 4).
CHARACTERIZATION OF THE SUBUNITS OF THE NFκB/REL FAMILY
INVOLVED IN IL-1β-INDUCED NFκB ACTIVATION
Nuclear extracts from IL-1β-stimulated HOC yielded two
specific electrophoretic bands in an electrophoretic mobility
shift assay (EMSA). The composition of these NFκB com-
plexes was analyzed with specific antibodies against two
different members of the NFκB/Rel proteins. For this pur-
pose, we incubated nuclear extracts from IL-1β-stimulated
HOC with 1 µg anti-p50 or/and anti-p65 antibodies. Anti-
body presence caused the appearance of slower migration
Fig. 1. IL-1β activates NFκB DNA binding in HOC. Cells were
incubated for 15, 30, 60, 90 and 120 min with 10 U/ml IL-1β. (A)
Representative autoradiogram of four different experiments with
similar results is shown. The specificity of the reaction was
established using competition assays with a 100-fold excess of
unlabeled NFκB (lane C). The positions of the specific NFκB
complexes are indicated. (B) Results of the densitometric analysis
for the specific NFκB binding are shown (mean±S.E.M.). *P<0.05 vs
0 min of incubation.
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complexes (shifted complexes) as shown in Fig. 5. Accord-
ing to these results, we concluded that the major band
(slower one) of NFκB complexes in our experiment was a
heterodimer p50–p65, while the minor band was not related
with these two proteins.
Using immunofluorescence assays, we have localized
these NFκB subunits in HOC. In control cells, a diffuse
cytoplasmic staining was seen, while cells incubated with
IL-1β had a clear nuclear staining pattern for p50 and p65,
indicating nuclear translocation of these NFκB subunits
[Fig. 6(A, B, E, F)]. Preincubation of HOC with 1000 mg/l
GS prevented the nuclear translocation of both subunits
[Fig. 6(D, H)].
NFκB activation occurs following dissociation of an in-
hibitory subunit, a member of the IκB family, which is
degraded by a proteolytic process. Therefore, we studied
the implication of the inhibitory protein IκBα in NFκB
activation in our system. In control HOC, IκBα was found
as a protein of approximately 37 KDa. After stimulation with
IL-1β, this band disappeared, suggesting IκBα degradation
(Fig. 7). Preincubation with GS prevented IκBα degradation
in HOC stimulated with IL-1β (Fig. 7).
EFFECT OF GS ON COX-1 AND COX-2 SYNTHESIS
In order to study whether the inhibition of NFκB activation
correlated with a decrease in the synthesis of COX-2, we
studied the effect of 1000 mg/l GS on COX-1 and COX-2
syntheses induced by IL-1β at 24 h of incubation. Results
of the experiments demonstrated that GS significantly
inhibited the protein synthesis of COX-2 measured by
Western blot. However, as shown in Fig. 8, neither IL-1β
nor GS modified the synthesis of COX-1.
We also investigated whether the ability of GS to inhibit
IL-1β enhanced COX-2 expression in HOC was due to the
inhibition of the corresponding gene expression. For this
purpose, GS-preincubated HOC were stimulated with IL-1β
for 24 h. Figure 9 shows that GS significantly inhibited
COX-2 expression.
EFFECT OF GS ON PGE2 PRODUCTION
In order to verify if the GS effect on COX-2 expression
and synthesis was related to a diminution of PGE2 concen-
tration in cell supernatants, we measured PGE2 release in
GS-preincubated HOC that were stimulated with IL-1β for 6
or 24 h. The sensitivity of PGE2 EIA was 36 pg/ml. The
basal release of PGE2 in unstimulated chondrocytes was
Fig. 2. Effect of GS on NFκB DNA binding induced by IL-1β. HOC
were preincubated for 30 min with different concentrations of GS
(10–1000 mg/l) and then stimulated with 10 U/ml IL-1β for 60 min.
(A) Representative autoradiogram of six different experiments with
similar results is shown. (B) Densitometric analysis for specific
NFκB complexes is shown (mean±S.E.M.). *P<0.05 vs basal;
†P<0.05 vs IL-1β alone.
Fig. 3. Effect of different sugars on IL-1β-induced NFκB DNA
binding. Chondrocytes were preincubated for 30 min with equimo-
lar concentrations of GS (1000 mg/l), Gal (2 mM) or N-AcG (2 mM)
and were then stimulated with 10 U/ml IL-1β for 60 min. Repre-
sentative autoradiogram of four different experiments with similar
results is shown.
Osteoarthritis and Cartilage Vol. 11, No. 4 293
nearly invariable for 6 or 24 h (see Table I). IL-1β stimula-
tion caused a time-dependent increase in PGE2 concen-
tration that was inhibited by 1000 mg/l GS both at 6 and
24 h (Table I).
Discussion
In this study, we have demonstrated that GS inhibits
NFκB activation induced by IL-1β in HOC. We have shown
that GS prevents IκBα degradation in the cell cytoplasm
and their migration to the nucleus of the subunits p50 and
p65. Furthermore, we have shown that preincubation of
HOC with GS inhibits the expression and synthesis of
COX-2, a NFκB-controlled protein with a key role in OA
pathogenesis.
IL-1β is a proinflammatory cytokine released by synovial
cells, chondrocytes and invading macrophages in inflamed
joints9,21. IL-1β plays a critical role in the inflammatory
process and the connective tissue destruction observed in
OA. This cytokine does activate other proinflammatory
cytokines, neutral proteases, growth factors and their re-
ceptors and the adhesion molecules, all contributors to
cartilage injury8. Indeed, synovial fluid from patients with
OA contains a high IL-1β concentration22.
Recently, some interesting studies regarding the effects
of GS in the treatment of OA have been published13,14. The
data indicate that GS acts as a symptom- and a structure-
modifying agent in the treatment of OA. However, the
mechanisms associated with these ways of action for GS
are still not totally clarified.
Although the origin of pain in OA is under discussion,
some explanations have been afforded, relating pain to
joint inflammation and local prostaglandin concentration. In
experimental animal models of inflammation, GS protected
animals from paw edema induced by bradykinin, serotonin
and histamine, and also GS impaired serositis induced by
carragenan as well as peritonitis induced by acetic acid or
formalin23. Furthermore, oral administration of GS had an
anti-inflammatory effect on adjuvant and kaolin-induced
arthritis in rats, although to a lesser extent than that seen
for traditional anti-inflammatory agents, such as indomet-
acin or acetylsalicylic acid24. Recent in vitro studies have
demonstrated that anti-inflammatory actions of GS can
be related to the suppression of neutrophil functions and
even to the inhibition of immune activity in the synovial
tissue25,26. In the present work, we have demonstrated that
GS inhibits NFκB activation and PGE2 synthesis induced
by IL-1β in human chondrocytes. NFκB is considered a key
regulator of tissue inflammation, since it controls the tran-
scription of a number of proinflammatory genes that regu-
late the synthesis of cytokines, chemokines and adhesion
molecules.
Fig. 4. Effect of GS on AP-1 DNA binding induced by IL-1β. HOC
were preincubated for 30 min with different concentrations of GS
(10–1000 mg/l) and were then stimulated with 10 U/ml IL-1β for
60 min. Representative autoradiogram of four different experi-
ments with similar results is shown.
Fig. 5. Determination of NFκB subunits in IL-1β-stimulated HOC.
The nuclear extracts were preincubated with antibodies against the
subunits p50 and p65 and were then analyzed for NFκB binding
activity. Supershifted bands (corresponding with major band for
specific NFκB complexes) were observed with anti-p50 and anti-
p65 antibodies (marked by arrows).
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We have shown that inhibition of NFκB activation was
related to the downregulation of the expression and syn-
thesis of COX-2, the enzyme responsible for PGE2 synthe-
sis in inflammatory situations. There are some NFκB
binding regions in the promotor of the COX-2 gene that can
account for the inhibition of COX-2 expression observed
with GS27. Several in vivo and in vitro studies have
approached the hypothesis of COX regulation by glucos-
amine, although the results seem controversial. Setnikar
et al. described that GS had no effect on the total COX
activity in inflamed rat paw tissues23. In this study, the dose
of GS used to treat rats may not result in critical tissue
levels required to achieve the effects described in the
present work. Lotz and co-workers found a downregulation
of COX-2 expression induced by IL-1 in human chondro-
cytes17. They demonstrate that this effect can not be
observed with different monosaccharides. These data are
in agreement with our results regarding the specificity of the
action of each sugar. However, they did not find any effect
of glucosamine on NFκB activity. In those experiments,
N-AcG was used instead of GS. This is an interesting point
since it has been suggested that these two drugs could
have different mechanisms of action25,28. Lotz et al. de-
scribed that N-AcG inhibited NO synthesis induced by
Fig. 6. Immunofluorescence assays for p50 (A–D) and p65 (E–H) subunits. In control cells, a slight cytoplasmatic immunostaining was seen
with anti-p50 and anti-p65 antibodies (A and E). When cells were treated for 60 min with 10 U/ml IL-1β, an intense nuclear fluorescence was
observed with both antibodies (B and F). Incubation with 1000 mg/l GS alone had no significant effect (C and G). GS preincubated
IL-1β-stimulated HOC showed a significant diminution in nuclear p50 and p65 immunostaining, showing an inhibition in the translocation of
the p50 and p65 subunits into the nuclei (D and H) in comparison with IL-1β-stimulated HOC.
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IL-1β, while opposite results have been published for GS29.
In this sense, it has been hypothesized that the sulfate
group could play a key role in the therapeutic action of
glucosamine salts28.
Our data strongly suggest that the impairment of NFκB
activation induced by GS could be responsible for a dimi-
nution in COX-2 expression and subsequent PGE2 synthe-
sis. GS could decrease NO concentration and even control
neutrophil functions (expression of adhesion molecules,
p38 phosphorylation or chemotaxis) through the inhibition
of the expression of NFκB-dependent genes17,25. There-
fore, NFκB inhibition could account for the beneficial effects
observed for this drug in joint inflammation. Other transcrip-
tion factors have been implicated in the COX-2 human
gene stimulation by IL-1β. In particular, C/EBP nuclear
factors have been demonstrated to regulate COX-2 expres-
sion in IL-1β-stimulated chondrocytes30. Additional studies
regarding the effect of GS on C/EBP binding to COX-2
promoter would be of interest.
The present study also describes the effect of GS on
NFκB subunits nuclear translocation. Preincubation with
GS inhibits both p50 and p65 migration to the nucleus.
Hence, the heterodimer p50–p65 was the major dimer
participating in NFκB activation induced by IL-1β in HOC.
These results seem particularly important since p50 sub-
unit has been linked to joint cartilage destruction during
inflammation, in contrast with other NFκB/Rel family
members31.
Besides anti-inflammatory properties, other mechanisms
of action can be additionally responsible for the specific
action of GS. OA is characterized by severe degradation of
matrix proteins, due to the activation of metalloproteinases
and increased degradation of proteoglycans3. Normaliza-
tion of articular cartilage metabolism could have structural
benefits resulting in an improvement in radiological signs.
Recent studies have demonstrated that GS can modify
collagenase activation29. GS was also able to restore the
dysregulated balance of glycosaminoglycan metabolism,
both preventing their degradation16,32,33 and stimulating
their production34,35. Mechanisms underlying these differ-
ent actions of GS are still poorly understood. However,
recent data have demonstrated that NFκB activity is essen-
tial for MMP-1 and MMP-3 upregulation36. Hence, GS
could have structural benefits on the OA-affected cartilage
through the inhibition of NFκB activation.
In these experiments, we have shown that GS is effective
in both preventing NFκB activation and COX-2 expression
and synthesis in a concentration ranging from 100 to
1000 mg/l (approximately 0.2 to 2 mM). A similar concen-
tration was previously described for collagenase inhibition
and proteoglycan production29,34. Pharmacokinetic studies
have shown that after oral administration of a therapeutic
dose of GS, a blood concentration of 0.1 mM glucosamine
can be achieved37. This concentration results from both
plasma-incorporated and free glucosamine. However, glu-
cosamine was also shown to accumulate in cartilage and
synovial cells29. Although in vitro data cannot be extrapo-
lated to pathophysiological conditions in humans, our data
suggest a novel mechanism of action by which GS could
modulate OA cartilage metabolism.
Fig. 7. GS increases IκBα levels in IL-1β-stimulated HOC. Cells
were treated with 10 U/ml IL-1β for 60 min after being preincu-
bated with 1000 mg/l GS for 30 min. Cytosolic extracts were
electrophoresed under reducing, denaturing conditions, stained
with affinity-purified anti-IκBα antibody, and visualized by en-
hanced chemiluminiscence. (A) Representative autoradiogram
of six different experiments with similar results is shown. (B)
Densitometric analysis corresponding to changes in IκBα levels,
corrected to those of α-tubulin is also shown (mean±S.E.M.).
*P<0.05 vs basal; †P<0.05 vs IL-1β alone.
Fig. 8. Effect of GS in HOC stimulated with IL-1β in COX-1 and
COX-2 protein syntheses. Cells were preincubated with GS
(1000 mg/l) for 30 min and were then stimulated with 10 U/ml IL-1β
for 24 h. (A) Representative Western blots corresponding to hy-
bridization with anti-COX-2, anti-COX-1 and anti-α-tubulin anti-
bodies are shown. (B) Densitometric analysis of COX-2 levels in
six different experiments, corrected to those of α-tubulin is shown
(mean±S.E.M.). *P<0.05 vs basal; †P<0.05 vs IL-1β alone.
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In summary, this study shows that GS inhibits NFκB
activation and COX-2 expression induced by IL-1β in OA
chondrocytes. The data further support the clinical findings
describing GS as a symptom- and structure-modifying drug
in the treatment of OA.
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